MAP1LC3B and lymphoma: Performance status was not significantly associated with the immunohistochemical factors studied, but it showed a trend of positive correlation with LC3B expression (p = 0.06, x2 = 3.3), since higher lymphoma LC3B expression was more often seen in patients with worse PS.